Migraine is the sixth most debilitating disease in the world. It cost the US economy approximately $36 billion per year in healthcare costs and lost productivity. A billion dollars is spent each year on brain imaging for headache sufferers. In fact, it’s so prevalent that 9 out of 10 people are unable to work or carry out regular tasks when suffering from a migraine.
Almagia offers the new migraine treatment device called ALMAG-03 that has the capability to reduce the severe headaches and make your life easier without pills.
In this blog, you will learn all about migraine and the studies that support the PEMF therapy of Almagia’s products.
Overview: Migraine
Migraines are brutally severe headaches that cause intense nausea and sensitivity to even minor abnormalities in the senses of sight, hearing, and touch. They are the world's third most frequent health disorder.
It has disrupted the lives of millions of people worldwide, forcing patients to take refuge in their beds. Migraines are a prevalent kind of headache that can cause severe, pulsating pain. According to the Migraine Research Foundation, migraines impact more than 39 million Americans, with women three times as likely than men to have them.
Research on the causes of migraine attacks imply that migraine sufferers' brains are compromised with regard to certain functions:
Cerebral circulation
Activity of the brain stem
Activity of the cerebral cortex
Nerve cell activity regulates emotion, arousal, and memory.
Its attacks include a variety of brain regions and neurotransmitters, and head pounding or throbbing, as well as sensitivity to light, sound, and vibrations.
What are the Case Studies on the New Migraine Treatment Device?
1.A double-blind, placebo-controlled study of 42 migraine patients (34 women and 8 men) was conducted to assess the impact of pulsing electromagnetic fields on their symptoms.
Subjects kept a baseline log of headache activity for a month before being randomly assigned to either actual or placebo pulsating electromagnetic fields applied to their inner thighs for 1 hour per day, 5 days per week, for 2 weeks.
After that, all individuals continued to jog for at least one month.
In the first month of follow-up, 73% of those who had genuine exposure reported fewer headaches (45% good, 14% excellent), compared to 50% of those who received a placebo (15% worse, 20% good, and 0% excellent).
After the initial month followup, 10 of the 22 participants who had real exposure received an additional two weeks of exposure.
All demonstrated decreased headache activity (50% good, 38% outstanding).
By the second month, 12 patients reported decreased headache activity (29% good, 43% outstanding).
After the first follow-up, 8 participants in the placebo group had 2 weeks of real exposure, with 75% experiencing reduced headache activity (38% good, 38% outstanding).
Thus, indicating that the inner thighs of pulsing electromagnetic fields, a new migraine treatment device like almag-03 is useful for migraines.
2. Another study to determine the effect of transcranial magnetic stimulation (TMS) on pain alleviation and autonomic nervous system (ANS) modulation in migraine patients.
The primary goal was to see if this new migraine treatment device might reduce migraine pain and alter heart rate variability, which is a measure of autonomic nervous system activity, in migraine patients.
The study included 42 individuals (36 females, mean age 41.43 to 11.69 years). Participants were randomly allocated to either the high or low TMS stimulation groups. Each subject received two short TMS pulses.
33 subjects had their heart rate variability (HRV) measured both before and after stimulation. The key outcomes assessed were changes in pain levels and HRV characteristics, such as mean heart rate, low-frequency (LF) and high-frequency (HF) power spectral regions, and the LF:HF ratio.
As a result, pain levels decreased by 75% after TMS treatment. Also, 32% of participants reported no headaches 24 hours after receiving one TMS session.
This new migraine infusion therapy using transcranial magnetic stimulation produces immediate and lasting pain decreases and causes profound changes in the parasympathetic neurological system.
Takeaway
Almagia has many products that are based on PEMF therapy. Almag-03 is one of the unique transcranial magnetic stimulation devices. It uses magnetic fields to treat numerous neurological diseases in a non-invasive manner.
This is one of the new migraine treatment devices that has quality assurance, maintenance, and guarantee by us.
Are you fed up of all those heavy doses of drugs? Visit our website to buy an amazing device for your migraine. Hurry!
Commentaires